IPP Bureau
Intracin Pharma secures APVMA nod to supply veterinary medicines in Australia
By IPP Bureau - June 03, 2026
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
Abbott highlights prognostic value of MRD testing for breast cancer recurrence
By IPP Bureau - June 03, 2026
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350
By IPP Bureau - June 03, 2026
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
Cipla appoints Taher Karampurwala as Senior Director and Head of Middle East Business
By IPP Bureau - June 03, 2026
Veteran pharmaceutical executive to relocate to Saudi Arabia and spearhead Cipla’s growth strategy across the Middle East region
CARE Hospitals strengthens advanced cardiac care
By IPP Bureau - June 03, 2026
The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries
Johnson & Johnson brings India’s first PFA technology for atrial fibrillation treatment
By IPP Bureau - June 03, 2026
New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure
CORONA Remedies receives EU-GMP certification for hormone facility
By IPP Bureau - June 02, 2026
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
Marksans Pharma to acquire Netherlands-based QliniQ
By IPP Bureau - June 02, 2026
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG
By IPP Bureau - June 02, 2026
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
Scientists develop rapid nanosensor to detect gut health biomarker for IBD and diabetes
By IPP Bureau - June 02, 2026
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial
By IPP Bureau - June 02, 2026
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
CellCarta and Leica Biosystems expand push to streamline precision medicine development
By IPP Bureau - June 02, 2026
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial
By IPP Bureau - June 02, 2026
The safety profile was described as manageable, though not without notable toxicities
Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial
By IPP Bureau - June 02, 2026
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
Ebola vax on the anvil?
By IPP Bureau - June 02, 2026
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
